LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Начало・Списък с акции・Beam Therapeutics Inc

Beam Therapeutics Inc

Затворен

СекторЗдравеопазване

28.82 -7.66

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

28.76

Максимум

30.28

Ключови измерители
By Trading Economics
Приходи	-339M -94M
Продажби	-82M 32M
EPS	-0.91
Марж на печалбата	-297.177
Служители	522
EBITDA	-362M -102M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+51.56% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-101M 3B
Предишно отваряне	36.48
Предишно затваряне	28.82

Настроения в новините

By Acuity

50%

147 / 344 Класиране в Healthcare

Beam Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.06.2026 г., 20:30 ч. UTC

Печалби

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2.06.2026 г., 23:58 ч. UTC

Пазарно говорене

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2.06.2026 г., 23:41 ч. UTC

Пазарно говорене

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2.06.2026 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2.06.2026 г., 23:01 ч. UTC

Придобивния, сливания и поглъщания

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2.06.2026 г., 23:00 ч. UTC

Придобивния, сливания и поглъщания

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2.06.2026 г., 22:57 ч. UTC

Пазарно говорене

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2.06.2026 г., 22:50 ч. UTC

Пазарно говорене

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2.06.2026 г., 21:07 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.06.2026 г., 21:07 ч. UTC

Пазарно говорене

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2.06.2026 г., 21:00 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

2.06.2026 г., 20:46 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:38 ч. UTC

Печалби

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2.06.2026 г., 20:21 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:12 ч. UTC

Печалби

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Product Rev $594M

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Adj EPS 85c >PANW

2.06.2026 г., 20:05 ч. UTC

Печалби

Palo Alto Networks 3Q Loss $177M >PANW

Сравнение с други в отрасъла

Ценова промяна

Beam Therapeutics Inc Прогноза

Ценова цел

By TipRanks

51.56% нагоре

12-месечна прогноза

Среден 49.91 USD 51.56%

Висок 80 USD

Нисък 26 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Beam Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Beam Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

147 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.